Research & Development

The Research Department of The SASSI Institute is dedicated to maximizing the accuracy and utility of our substance use measures and expanding the Institute’s services to better meet practitioners’ needs. We are involved in collaborative relationships with many SASSI users in the process of gathering data for our research. We are also pleased to consult with SASSI users regarding their research.

Contact our Research Department at research@sassi.com if you have questions or need assistance with any research related aspects of our instruments.

Data Sharing 
If you wish to assist The SASSI Institute by using our instruments and sharing your data to help us further develop, update, and validate our instruments, please e-mail research@sassi.com.

Research Updates from the Blog!

Criminal Justice Publication Accepted

April 22, 2021

Hello friends and colleagues, We hope you and your families are all doing well. We wanted to call your attention to our very latest peer reviewed publication, released earlier this month. The title is: Criminal Justice Alcohol and Drug Screening in Practice: Using the Substance Abuse Subtle Screening Inventory to Identify Substance Use Disorder in Offenders. Now in its fourth iteration (SASSI-4), this article discusses the SASSI screening tools’ utility with criminal offenders and reviews… Read more

New Publication!

January 28, 2021

The SASSI Institute is pleased to announce the publication of its newest manuscript “Mental Health and Substance Use Disorder Co-Morbidities Among Teens in Treatment: SASSI-A3 Correlations in Screening Scores.” Within this article, we review data from teenagers in treatment focusing on mental health diagnoses alongside a DSM-5 diagnosis of substance use disorder. Our hope is that by identifying possible correlations between SASSI-A3 scale scores and diagnosed mental health disorders, (depression and anxiety in particular), will… Read more

Coronavirus Vaccine Hopes

November 19, 2020

Dear Friends, On Monday, November 9th,the CEO of Pfizer announced positive early results from its coronavirus vaccine trial, citing an over 90% effectiveness rate during its first phase of clinical trials. This is truly monumental news of worldwide significance. This fact has renewed hope throughout the country, indeed throughout the world, that we were finally coming closer to achieving a response to this deadly Pandemic. We at The SASSI Institute maintain our fervent hopes that… Read more

Adolescent Vaping: Examining the Dangers

October 15, 2020

It is with great pride that we announce the release of our latest adolescent research manuscript. This article is based on one key aspect of the Substance Abuse Subtle Screening Inventory (SASSI) Institute’s forthcoming third iteration of the Adolescent Substance Abuse Subtle Screening Inventory (SASSI-A3). While our primary goal was to develop a screening tool for adolescents that is concordant with the diagnostic and statistical manual of mental disorders, Fifth Edition (DSM-5) guidelines, we found… Read more

Adolescent SASSI-A3 Available December 1st, 2020

October 1, 2020

Our Team at the Institute has been working tirelessly on a two-year research project to bring you an updated adolescent instrument that is validated against the DSM-5 diagnostic criteria.  Our research has produced multiple publications and allowed the SASSI-A3 to include some new features, including a brief scale, Prescription Drug (Rx), to accurately identify teens likely to be abusing prescription medications. The updated version also includes new subtle items to reflect current teen alcohol and… Read more

Coming Soon: Adolescent SASSI-A3

September 3, 2020

               We wanted to provide you some important SASSI updates. We’re excited to announce that the research findings on the adolescent SASSI-A3 have been published! Within the coming weeks and next few months, we will be concentrating our efforts on publishing the SASSI-A3 instrument, which similarly to the adult screening tool, now includes a prescription drug scale and greater sensitivity to opioids and prescription medications. The updated instrument will be available on our online platform… Read more